Multivalent effects of RGD peptides obtained by nanoparticle display
- PMID: 17004722
- DOI: 10.1021/jm060515m
Multivalent effects of RGD peptides obtained by nanoparticle display
Abstract
The binding of RGD peptides to integrins offers an excellent system to study the multivalent mediated changes in affinity that arise when peptides, displayed on the surface of a nanoparticle carrier, bind to integrins displayed on the cell membrane. The IC50 of an RGD nanoparticle for endothelial adhesion was 1.0 nM nanoparticle or 20 nM peptide (20 peptide/nanoparticle) and was associated with strong multivalent effects, defined as a multivalent enhancement factor (MVE) of 38 (MVE=IC50 (peptide)/IC50 (peptide when displayed by nanoparticle)). The attachment of RGD peptides to nanoparticles resulted in an extension of the peptide blood half-life from 13 to 180 min. Based on the multivalent enhancement of affinity and extension of blood half-life, multivalent RGD nanoparticle-sized materials should be potent inhibitors of the alpha(V)beta(3) function on endothelial cells in vivo.
Similar articles
-
Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.J Nucl Med. 2004 Oct;45(10):1776-83. J Nucl Med. 2004. PMID: 15471848
-
In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3.Int J Pharm. 2009 Feb 23;368(1-2):89-97. doi: 10.1016/j.ijpharm.2008.09.055. Epub 2008 Oct 17. Int J Pharm. 2009. PMID: 18992308
-
(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.J Nucl Med. 2007 Jul;48(7):1162-71. doi: 10.2967/jnumed.107.039859. Epub 2007 Jun 15. J Nucl Med. 2007. PMID: 17574975
-
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature.Drug Resist Updat. 2005 Dec;8(6):381-402. doi: 10.1016/j.drup.2005.10.002. Epub 2005 Nov 23. Drug Resist Updat. 2005. PMID: 16309948 Review.
-
RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis.Mol Pharm. 2012 Nov 5;9(11):2961-73. doi: 10.1021/mp3002733. Epub 2012 Oct 4. Mol Pharm. 2012. PMID: 22967287 Review.
Cited by
-
Bioengineering strategies for designing targeted cancer therapies.Adv Cancer Res. 2013;118:1-59. doi: 10.1016/B978-0-12-407173-5.00002-9. Adv Cancer Res. 2013. PMID: 23768509 Free PMC article. Review.
-
Multivalent porous silicon nanoparticles enhance the immune activation potency of agonistic CD40 antibody.Adv Mater. 2012 Aug 2;24(29):3981-7. doi: 10.1002/adma.201200776. Epub 2012 Jun 12. Adv Mater. 2012. PMID: 22689074 Free PMC article.
-
Magnetic Iron Oxide Nanoparticles for Disease Detection and Therapy.Mater Today (Kidlington). 2019 Dec;31:86-99. doi: 10.1016/j.mattod.2019.06.003. Epub 2019 Jun 22. Mater Today (Kidlington). 2019. PMID: 32831620 Free PMC article.
-
Enhanced cellulose degradation using cellulase-nanosphere complexes.PLoS One. 2012;7(8):e42116. doi: 10.1371/journal.pone.0042116. Epub 2012 Aug 1. PLoS One. 2012. PMID: 22870287 Free PMC article.
-
Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.Int J Nanomedicine. 2012;7:5889-900. doi: 10.2147/IJN.S36847. Epub 2012 Nov 27. Int J Nanomedicine. 2012. PMID: 23226020 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources